Morbidly Adherent Placenta
8
0
0
2
Key Insights
Highlights
Success Rate
100% trial completion (above average)
Treatment Research
6 treatments under study, led by Hif 1α And Lc3b Expression And Mmp9 Level
Research Leaders
11 sponsors active, led by Cairo University
Related Conditions
Often studied with 6 related conditions
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 50/100
0.0%
0 terminated out of 8 trials
100.0%
+13.4% vs benchmark
0%
0 trials in Phase 3/4
0%
0 of 2 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.6%
Based on 2 completed trials
Clinical Trials (8)
Hypoxia-induced Autophagy in the Pathogenesis of MAP
Diagnostic Accuracy of a Specialized Pro Forma in Assessing Morbidly Adherent Placenta With Correlation to Intra-operative Findings
Morbidly Adherent Placenta, Diagnosis and Proper Management
Role of Ultrasound in Diagnosis of Placenta Previa and MAP
Psychological Outcome of Women With Morbidly Adherent Placenta Following Hystrectomy
Comparison Between Bladder Dissection Before and After Uterine Incision in Cesarean Section for Morbidly Adherent Placenta
Delivery Timing in Morbidly Adherent Placentas: a Randomized, Controlled Trial
Cell-free Fetal DNA Circulating in the Maternal Plasma as a Marker for Morbidly Adherent Placenta
Research Network
Common Treatments
- Hif 1α And Lc3b Expression And Mmp9 Level1
- Scheduled Timing Of Delivery1
- Ultrasound1
- Bladder Dissection1
- Two Dimensional Ultrasonography Power And Color Doppler1
Active Sponsors
- Cairo University2
- University Hospital, Angers1
- Assiut University1
- National Research Centre, Egypt1
- Aljazeera Hospital1
Top Investigators
Algazeerah hospital -Location (Giza -Egypt ) and National Research centre egypt
Inserm U1153, Obstetrical, Perinatal and Pediatric Epidemiology Research Team, Paris, France
Ain Shams Maternity Hospital
Related Conditions
- Placenta Accreta2
- Placenta Increta1
- Placenta1
- Autophagy1
- Placenta Percreta1